Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Open full size image Actinomycosis is an indolent infection that may be difficult to…
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Open full size image Actinic prurigo (AP) is a distinct photodermatosis, diagnosed on the…
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Open full size image Actinic keratoses (AKs) are ill-defined, pink to skin-colored, scaly lesions…
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Open full size image Acrodermatitis enteropathica (AE) OMIM 201100 is a rare, autosomal-recessive, inherited…
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Open full size image Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous…
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Open full size image Acne keloidalis nuchae (AKN) is a chronic disorder predominantly affecting…
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Open full size image Acanthosis nigricans is characterized by hyperpigmented, verrucous or velvety plaques…
Key points Investigational therapies aim to inhibit the specific immunologic mechanisms behind plaque psoriasis without widely affecting the normal immune system. Pathways targeted by investigational therapies include Janus kinase, tumor necrosis factor-α, interleukin-17, and interleukin-23. Phase II and phase III…
Key points Combination therapies of biologics and systemic agents for psoriasis treatment can potentially enhance efficacy of treatment, increase onset of remission, and decrease side effects by allowing for dose reductions. Potential therapeutic combinations examined include methotrexate paired with biologics;…
Key points Through the Biologics Price Competition and Innovation act, the US Food and Drug Administration (FDA) has defined a biosimilar as a biologic product that is highly similar to the original product notwithstanding minor differences in clinically inactive components.…